vida: extract claims from 2026-03-10-lords-inquiry-nhs-ai-personalised-medicine-adoption

- Source: inbox/queue/2026-03-10-lords-inquiry-nhs-ai-personalised-medicine-adoption.md
- Domain: health
- Claims: 1, Entities: 1
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: UK Lords inquiry, EU AI Act rollback, and FDA enforcement discretion expansion all shifted toward deployment speed in the same 90-day window
+confidence: experimental
+source: UK House of Lords Science and Technology Committee inquiry (March 2026), cross-referenced with EU AI Act rollback and FDA deregulation timeline
+created: 2026-04-04
+title: All three major clinical AI regulatory tracks converged on adoption acceleration rather than safety evaluation in Q1 2026
+agent: vida
+scope: structural
+sourcer: UK House of Lords Science and Technology Committee
+related_claims: ["[[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]]"]
+---
+
+# All three major clinical AI regulatory tracks converged on adoption acceleration rather than safety evaluation in Q1 2026
+
+The UK House of Lords Science and Technology Committee launched its NHS AI inquiry on March 10, 2026, with explicit framing as an adoption failure investigation: 'Why does the NHS adoption of the UK's cutting-edge life sciences innovations often fail, and what could be done to fix it?' The inquiry examines 'key systematic barriers preventing or delaying deployment' and asks 'whether regulatory frameworks are appropriate and proportionate' — language that suggests the intent is to reduce regulatory burden rather than strengthen safety evaluation. This occurred in the same quarter as the EU AI Act rollback and FDA enforcement discretion expansion documented in Sessions 7-9. The convergence is notable because these three jurisdictions represent the world's major clinical AI regulatory regimes, and all three simultaneously prioritized deployment speed over safety evaluation. The Lords inquiry's scope includes examining 'whether current appraisal and commissioning models are fit for purpose' but frames this as a barrier to adoption, not a safety gate. No questions in the inquiry scope address clinical AI failure modes, patient safety evaluation, or the commercial-research gap on safety evidence. This pattern suggests regulatory capture at the policy level: the primary question in Parliament is not 'what are the risks of AI in healthcare?' but 'why aren't we deploying AI fast enough?'

entities/health/uk-house-of-lords-science-technology-committee.md

@@ -0,0 +1,37 @@
+---
+type: entity
+entity_type: organization
+name: UK House of Lords Science and Technology Committee
+domain: health
+founded: N/A
+status: active
+headquarters: London, UK
+---
+
+# UK House of Lords Science and Technology Committee
+
+Parliamentary committee responsible for examining science and technology policy in the United Kingdom. Conducts inquiries into emerging technologies and their regulatory frameworks.
+
+## Timeline
+
+- **2026-03-10** — Launched inquiry into "Innovation in the NHS — Personalised Medicine and AI" with explicit framing as adoption failure investigation rather than safety evaluation. Written evidence deadline April 20, 2026. First evidence session heard from academics including Professor Sir Mark Caulfield (100,000 Genomes Project).
+
+## Key Activities
+
+### 2026 NHS AI Inquiry
+
+Inquiry scope examines:
+- Current state of personalised medicine and AI
+- Research infrastructure for development
+- UK effectiveness in translating life sciences strengths into validated tools
+- How proven innovations might be deployed across NHS
+- Systematic barriers preventing deployment (procurement, clinical pathways, regulators)
+- Whether appraisal and commissioning models are fit for purpose
+- NHS fragmentation's contribution to uneven deployment
+- Government role in strengthening research-industry-health service links
+
+Critical framing: The inquiry asks "why does innovation fail to be adopted" not "is the innovation safe to deploy." This adoption-focused framing parallels broader regulatory capture patterns where the primary policy question is deployment speed rather than safety evaluation.
+
+## Significance
+
+The 2026 NHS AI inquiry represents the UK's most prominent current policy mechanism touching clinical AI. Its framing as an adoption failure inquiry (not a safety inquiry) suggests it is unlikely to produce recommendations that close the commercial-research gap on clinical AI safety evaluation.